Beta Thalassemia Major Clinical Trial
Official title:
A Pilot Trial to Assess the Feasibility and Safety of GCSF Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
Betathalassemia major is a disease of the blood and bone marrow. You were born with it and
it has made you unable to make normal hemoglobin and red cells. You have been receiving red
blood cell transfusions all your life. These transfusions do not cure your disease. The
problem with transfusions is that they contain a lot of iron. With time iron builds up in
your body and will eventually hurt some of your organs . Because of this buildup of iron ,
you are taking medicine that helps your body get rid of the extra iron.
Today, the only other treatment is bone marrow or stem cell transplant. It can only be done
when a matched donor is available. This is most often a brother, sister, or parent. Bone
marrow transplant may cure betathalassemia major. If you have a transplant and it is
successful, you will no longer have the disease. Without a matched sibling or parent, the
standard treatment is to keep having transfusions.
In the near future, we will be testing a new treatment for making normal hemoglobin and
normal red blood cells. We have recreated the healthy hemoglobin gene in a test tube. We are
able to use it and put it back into cells. This is called gene therapy. We have been able to
put this gene into the stem cells of mice with thalassemia. These mice were cured. We now
plan to take that gene and put it into stem cells from people who have betathalassemia
major. We will then inject those stem cells back into that person's blood.
In general, we can obtain more stem cells from the blood of a person than from the bone
marrow . In order to do so, we must give that person a blood growth factor. The growth
factor stimulates the bone marrow to make more stem cells. That growth factor is called
granulocyte colony stimulating factor (GCSF), or Filgrastim.
The purpose of this trial is to find out if the drug GCSF has any side effects on you, and
if you will make more stem cells in response to it. This trial is not a gene therapy trial.
This trial will not help your thalassemia.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03276455 -
Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified
|
Phase 1/Phase 2 | |
| Completed |
NCT02674607 -
the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children
|
N/A | |
| Terminated |
NCT01571635 -
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
|
Phase 2 | |
| Completed |
NCT04092205 -
Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation
|
Phase 2 | |
| Completed |
NCT02744560 -
Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C
|
N/A | |
| Recruiting |
NCT06466304 -
Inspiratory Muscle Training in Children With Beta Thalasemia
|
N/A | |
| Recruiting |
NCT04353986 -
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
|
Phase 3 | |
| Not yet recruiting |
NCT02173951 -
An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT03947632 -
Anthropometric Measurements in Children Having Transfusion-dependent Beta Thalassemia
|
||
| Withdrawn |
NCT04776850 -
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
|
Early Phase 1 | |
| Completed |
NCT02744547 -
Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C
|
N/A | |
| Completed |
NCT02744105 -
Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C
|
N/A | |
| Active, not recruiting |
NCT03101423 -
Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism
|
N/A | |
| Completed |
NCT02671695 -
Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia
|
N/A |